Skip to main content

Advertisement

SpringerLink
Log in

Androgen deprivation therapy for prostate cancer: Implications for cardiometabolic clinical care

  • Review Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Prostate cancer (PCa) is the most common malignancy in men. Androgen deprivation therapy (ADT) plays an important role in the management of locally advanced and metastatic PCa. Its use in combination with external beam radiation and as an adjuvant therapy has resulted in improved survival in a subset of patients with locally advanced disease. In men with metastatic disease, ADT results in improvement in pain and overall quality of life. In addition to these two clinical settings where ADT has proven benefits, it is also being increasingly used in patients experiencing biochemical recurrence and those with early stage localized disease, even though no survival advantage has been demonstrated. ADT has significant adverse effects such as sexual dysfunction, decreased lean mass, increased fat mass, decreased quality of life, anemia, and osteoporosis. Recently, insulin resistance, diabetes, and metabolic syndrome have emerged as complications of ADT. Some data also suggests that ADT might be responsible for incident cardiovascular disease. Since the majority of men with PCa die of conditions other than their malignancy, recognition and management of these adverse effects is important. This paper serves as a focused review of recent studies examining the metabolic abnormalities and cardiovascular disease related to ADT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Basaria S. Androgen deprivation therapy, insulin resistance and cardiovascular mortality: An inconvenient truth. J Androl 2008, 29: 534–9.

    Article  PubMed  Google Scholar 

  2. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomicand racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61: 212–36.

    Article  PubMed  Google Scholar 

  3. Wilt T, Nair B, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostate cancer. Cochrane Database Syst Rev 2002, 1: CD003506.

    PubMed  Google Scholar 

  4. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. New Engl J Med 1997, 337: 295–300.

    Article  PubMed  Google Scholar 

  5. Bolla M, de Reijke TM, Van Tienhoven G et al. Duration of androgen suppression in the treatment of prostate cancer. New Engl J Med 2009, 360: 2516–27.

    Article  PubMed  Google Scholar 

  6. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer. New Engl J Med 1999, 341: 1781–8.

    Article  PubMed  Google Scholar 

  7. Shahani S, Braga-Basaria M, Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 2008, 93: 2042–9.

    Article  PubMed  Google Scholar 

  8. Chodak GW, Keane T, Klotz L; Hormone Therapy Study Group. Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology 2002, 60: 201–8.

    Article  PubMed  Google Scholar 

  9. Tammela T. Endocrine treatment of prostate cancer. J Steroid Biochem Mol Biol 2004, 92: 287–95.

    Article  PubMed  Google Scholar 

  10. Huggins C, Stevens RE Jr, Hodges CV. Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941, 43: 209–23.

    Article  Google Scholar 

  11. Smith MR. Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes 2007, 14: 247–54.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Paulson DF. Management of metastatic prostate cancer. Urology 1985, 25 (Suppl): 49–52.

    Article  PubMed  Google Scholar 

  13. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial. Lancet 2002, 360: 103–6.

    Article  PubMed  Google Scholar 

  14. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008, 26: 2497–04.

    Article  PubMed  Google Scholar 

  15. Denham JW, Steigler A, Lamb DS, et al; Trans-Tasman Radiation Oncology Group. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomized controlled trial. Lancet Oncol 2005, 6: 841–50.

    Article  PubMed  Google Scholar 

  16. D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008, 299: 289–95.

    PubMed  Google Scholar 

  17. Roach M III, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008, 26: 585–91.

    Article  PubMed  Google Scholar 

  18. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005, 61: 1285–90.

    Article  PubMed  Google Scholar 

  19. Moul JW, Bañez LL, Freedland SJ. Rising PSA in nonmetastatic prostate cancer. Oncology (Williston Park) 2007, 21: 1436–45.

    Google Scholar 

  20. Wang H, Wallner K, Sutlief S, Blasko J, Russell K, Ellis W. Transperineal brachytherapy in patients with large prostate glands. Int J Cancer 2000, 90: 199–205.

    Article  PubMed  Google Scholar 

  21. Sharifi N, Gulley JL, Dahut WL An update on androgen deprivation therapy for prostate cancer. Endocr-relat cancer 2010, 17: 305–15.

    Article  Google Scholar 

  22. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005, 103: 1615–24.

    Article  PubMed  Google Scholar 

  23. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999, 17: 3461–7.

    PubMed  Google Scholar 

  24. Strum SB, Scholz MC, McDermed JE. termittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy. Oncologist 2005, 5: 45–52.

    Article  Google Scholar 

  25. Basaria S, Lieb J 2nd, Tang AM, et al. Long term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol 2002, 56: 779–86.

    Article  Google Scholar 

  26. Harle LK, Maggio M, Shahani S, Braga-Basaria M, Basaria S. Endocrine complications of androgen-deprivation therapy in men with prostate cancer. Clin Adv Hematol Oncol 2006, 4: 687–96.

    PubMed  Google Scholar 

  27. Corona G, Rastrelli G, Monami M, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol 2011, 165: 687–701.

    Article  PubMed  Google Scholar 

  28. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011, 96: 3007–19.

    Article  PubMed Central  PubMed  Google Scholar 

  29. Satariano WA, Ragland KE, van den Eeden SK. Cause of death in men diagnosed with prostate carcinoma. Cancer 1998, 83: 1180–8.

    Article  PubMed  Google Scholar 

  30. Riihimäki M, Thomsen H, Brandt A, Sundquist J, Hemminki K. What do prostate cancer patients die of? Oncologist 2011, 16: 175–81.

    Article  PubMed Central  PubMed  Google Scholar 

  31. Kumar RJ, Barqawi A, Crawford ED. Adverse events associated with hormonal therapy for prostate cancer. Rev Urol 2005, 7: S37–43.

    PubMed Central  PubMed  Google Scholar 

  32. Stone P, Hardy J, Huddart R, A’Hern R, Richards M. Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 2000, 36: 1134–41.

    Article  PubMed  Google Scholar 

  33. Kiratli BJ, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Adult Urology 2001, 57: 127–32.

    Article  Google Scholar 

  34. Bhasin S, Taylor WE, Singh R, et al. The mechanisms of androgen effects on body composition: mesenchymal pluripotent cell as the target of androgen action. J Gerontol A Biol Sci Med Sci 2003, 58: M1103–10.

    Article  PubMed  Google Scholar 

  35. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 2009, 181: 1998–2008.

    Article  PubMed Central  PubMed  Google Scholar 

  36. Smith, MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002, 87: 599–603.

    Article  PubMed  Google Scholar 

  37. Smith JC, Bennett S, Evans M, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001, 86: 4261–7.

    Article  PubMed  Google Scholar 

  38. Lee H, McGovern K, Finkelstein J, Smith MR. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer 2005, 104: 1633–7.

    Article  PubMed  Google Scholar 

  39. Smith MR, Lee H, McGovern F, et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 2008, 112: 2188–94.

    Article  PubMed Central  PubMed  Google Scholar 

  40. van Londen GJ, Levy ME, Perera S, Nelson JB, Greenspan SL. Body composition changes during androgen deprivation therapy for prostate cancer: A 2-year prospective study. Crit Rev Oncol Hematol 2008, 68: 172–7.

    Article  PubMed Central  PubMed  Google Scholar 

  41. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006, 91: 1305–8.

    Article  PubMed  Google Scholar 

  42. Nishiyama T, Ishizaki F, Tsutomu A, Shimura H, Takahashi K. The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab 2005, 90: 657–60.

    Article  PubMed  Google Scholar 

  43. Basaria S, Muller DC, Carducci MA, Egan J, Dobs, AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen deprivation therapy. Cancer 2006, 106: 581–8.

    Article  PubMed  Google Scholar 

  44. Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006, 24: 4448–56.

    Article  PubMed  Google Scholar 

  45. Alibhai SM, Duong-Hua M, Sutradhar R, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009, 27: 3452–8.

    Article  PubMed  Google Scholar 

  46. Keating N, O’Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease with androgen deprivation therapy: Observational study of veterans with prostate cancer. J Natl Cancer Inst 2010, 102: 39–46.

    Article  PubMed Central  PubMed  Google Scholar 

  47. Derweesh IH, Diblasio CJ, Kincade MC, et al. Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU Int 2007, 100: 1060–5.

    PubMed  Google Scholar 

  48. Hakimian P, Blute M Jr, Kashanian J, Chan S, Silver D, Shabsigh R. Metabolic and cardiovascular effects of androgen deprivation therapy. BJU Int 2008, 120: 1509–14.

    Article  Google Scholar 

  49. Alberti KG, Eckel RH, Grundy SM, et al; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120: 1640–5.

    Article  PubMed  Google Scholar 

  50. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288: 2709–16.

    Article  PubMed  Google Scholar 

  51. Laaksonen DE, Niskanen L, Punnonen K, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004, 27: 1036–41.

    Article  PubMed  Google Scholar 

  52. Bagrodia A, Diblasio CJ, Wake RW, Derweesh IH. Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues. Int J Urol 2009, 25: 169–76.

    Google Scholar 

  53. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen deprivation therapy. J Clinl Oncol 2006, 24: 3979–83.

    Article  Google Scholar 

  54. Brown BW, Brauner C, Minnotte MC. Noncancer deaths in white adult cancer patients. J Natl Cancer Inst 1993, 85: 979–87.

    Article  PubMed  Google Scholar 

  55. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS; And the Urologic Diseases in America Project. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007, 110: 1493–500.

    Article  PubMed  Google Scholar 

  56. Tsai HK, D’Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007, 99: 1516–24.

    Article  PubMed  Google Scholar 

  57. Nanda A, Chen MH, Braccioforte MH, Moran BJ, D’Amico AV. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 2009, 302: 866–73.

    Article  PubMed  Google Scholar 

  58. Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 2008, 54: 816–23.

    Article  PubMed  Google Scholar 

  59. Roach M 3rd, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008, 26: 585–91.

    Article  PubMed  Google Scholar 

  60. Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 2009, 27: 92–9.

    Article  PubMed Central  PubMed  Google Scholar 

  61. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005, 365: 1415–28.

    Article  PubMed  Google Scholar 

  62. Shahani S, Braga-Basaria M, Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk of atherosclerosis. J Clin Endocrinol Metab 2008, 93: 2042–9.

    Article  PubMed  Google Scholar 

  63. Martín-Merino E, Johansson S, Morris T, García Rodríguez LA. Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: A nested case-controlled study in UK primary care. Drug Saf 2011, 34: 1061–77.

    Article  PubMed  Google Scholar 

  64. Azoulay L, Yin H, Benayoun S, Renoux C, Boivin JF, Suissa S. Androgen deprivation therapy and the risk of stroke in patients with prostate cancer. Euro Urol 2011, 60: 1244–50.

    Article  Google Scholar 

  65. Levine GN, D’Amico AV, Berger P, et al; American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 2010, 121: 833–40.

    Article  PubMed Central  PubMed  Google Scholar 

  66. Baumann FT, Zopf EM, Bloch W. Clinical exercise intervention in prostate cancer patients — a systematic review of randomized controlled trials. Support Care Cancer 2012, 20: 221–33.

    Article  PubMed  Google Scholar 

  67. Nobes JP, Langley SE, Klopper T, Russell-Jones D, Laing RW. A prospective, randomized pilot study evaluating effects of metformin and lifestyle interventions on patients with prostate cancer receiving androgen deprivation therapy. BJU Int 2011, Sep 20 [Epub ahead of print]; doi: 10.1111/j.1464-410X.2011.10555.x.

Download references

Author information

Authors and Affiliations

  1. Boston University Medical Center, Boston, MA, USA

    L. Collins & S. Basaria MD

  2. University of Southern Illinois Medical College, Springfield, IL, USA

    N. Mohammed

  3. Mercy Catholic Medical Center, Drexel University College of Medicine, Phildelphia, PA, USA

    T. Ahmad

Authors
  1. L. Collins
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Mohammed
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Ahmad
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Basaria MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Basaria MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Collins, L., Mohammed, N., Ahmad, T. et al. Androgen deprivation therapy for prostate cancer: Implications for cardiometabolic clinical care. J Endocrinol Invest 35, 332–339 (2012). https://doi.org/10.3275/8284

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.3275/8284

Key-words

Search

Navigation